These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34821004)

  • 21. Emicizumab-kxwh: First Global Approval.
    Scott LJ; Kim ES
    Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utilization of emicizumab in acquired hemophilia A: A case report.
    Yates SG; Webb CB; Sarode R; Ibrahim IF; Shen YP
    Transfus Apher Sci; 2022 Dec; 61(6):103457. PubMed ID: 35643753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors.
    Brophy DF; Martin EJ; Kuhn J
    Haemophilia; 2019 Mar; 25(2):e121-e123. PubMed ID: 30748061
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utilization of emicizumab in the treatment of a case of acquired hemophilia A.
    Ocaña Gómez MÁ; Esquivel Negrín J; Ríos De Paz M; De Dios García MD
    Farm Hosp; 2024; 48(1):45-47. PubMed ID: 37468348
    [No Abstract]   [Full Text] [Related]  

  • 26. [Emicizumab: a paradigm shift in hemophilia treatment].
    Nogami K
    Rinsho Ketsueki; 2020; 61(5):536-541. PubMed ID: 32507821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reappearance of inhibitor in a tolerized patient with severe haemophilia A during FVIII-free emicizumab therapy.
    Capdevila L; Borgel D; Lasne D; Lacroix-Desmazes S; Desvages M; Delignat S; Bally C; Frenzel L; Harroche A
    Haemophilia; 2021 Jul; 27(4):e581-e584. PubMed ID: 34004050
    [No Abstract]   [Full Text] [Related]  

  • 28. Initiation of emicizumab prophylaxis in an infant with haemophilia A and subdural haemorrhage.
    Bush KA; Lucas TL; Haley KM; Thornburg CD
    Haemophilia; 2020 Nov; 26(6):e353-e355. PubMed ID: 32892446
    [No Abstract]   [Full Text] [Related]  

  • 29. Chromogenic Factor VIII Assay for Patients with Hemophilia A and on Emicizumab Therapy.
    Yacoub OA; Duncan EM
    Methods Mol Biol; 2023; 2663():597-610. PubMed ID: 37204739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab.
    Dargaud Y; Lienhart A; Janbain M; Le Quellec S; Enjolras N; Negrier C
    Haematologica; 2018 Apr; 103(4):e181-e183. PubMed ID: 29472355
    [No Abstract]   [Full Text] [Related]  

  • 31. Rapidly loading emicizumab without immunosuppression in acquired haemophilia.
    Ragni MV
    Lancet Haematol; 2023 Nov; 10(11):e870-e871. PubMed ID: 37858327
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
    Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
    Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emicizumab: the hemophilia A game-changer.
    Alcedo Andrade PE; Mannucci PM; Kessler CM
    Haematologica; 2024 May; 109(5):1334-1347. PubMed ID: 37916312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
    Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
    Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The factor VIII heavy chain improves emicizumab-tenase assembly to enhance the factor VIII-mimicking cofactor activity.
    Minami H; Nogami K; Soeda T; Kitazawa T; Hattori K; Shima M
    Thromb Res; 2018 Jun; 166():77-79. PubMed ID: 29684725
    [No Abstract]   [Full Text] [Related]  

  • 36. Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab.
    Miller CH; Boylan B; Payne AB; Driggers J; Bean CJ
    Int J Lab Hematol; 2021 Apr; 43(2):e84-e86. PubMed ID: 33174329
    [No Abstract]   [Full Text] [Related]  

  • 37. In vitro evaluation of global coagulation potentials in the co-presence of plasma-derived factors Viia/X products (Byclot
    Nakajima Y; Takami E; Nakano H; Nogami K
    Haemophilia; 2022 Sep; 28(5):e149-e152. PubMed ID: 35947585
    [No Abstract]   [Full Text] [Related]  

  • 38. Budget Impact of Emicizumab for Routine Prophylaxis of Bleeding Episodes in Patients With Hemophilia A With Inhibitors.
    Watanabe AH; Lee SWH; Chai-Adisaksopha C; Lim MY; Chaiyakunapruk N
    Value Health Reg Issues; 2022 Mar; 28():7-13. PubMed ID: 34800834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.
    Kitazawa T; Shima M
    Int J Hematol; 2020 Jan; 111(1):20-30. PubMed ID: 30350119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
    Lenting PJ; Denis CV; Christophe OD
    Blood; 2017 Dec; 130(23):2463-2468. PubMed ID: 29042366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.